InHANSE Institute of Head and Neck Studies and Education Contact Us

 

COVID-19

 

Prof Hisham Mehanna has recently led an international collaboration to develop consensus guidelines on head and neck cancer practice in acutely resource-constrained settings, such as COVID-19, that have been accepted for publication by Lancet Oncology.

The recommendations were co-ordinated by the Head and Neck Cancer International Group, which is a collaboration of 20 national clinical trials groups in head and neck cancer. Hisham is the Chair of the group.

They brought together a consortium of 35 international and national bodies dealing with the management of head and neck cancer, and undertook a Delphi consensus process online with nominees from each of the bodies. The three rounds were undertaken and analysed in less than 2 weeks and the paper was then written and submitted for endorsement by 39 international bodies within a week after that. The paper has now been accepted by Lancet Oncology and is due to come out in the middle of June.

These guidelines have been endorsed by 39 different national and international bodies from California to China and Sweden to South Africa, and are now adopted as the international guidelines for the COVID-19 pandemic, and other acute disasters in future.

  

 

 

COVID-19

5 Jun 20 - Prof Mehanna collaborating on international guidelines

 
Dr Jenny Bryant leaves InHANSE

Dr Jenny Bryant leaves InHANSE

12 Nov 19 - Jennifer Bryant left InHANSE on Friday

 
 

Professor Mehanna speaking in New Zealand

16 Oct 19 - Professor Mehanna to give Prestigious lecture

 
Valued member retires

Valued member retires

5 Apr 19 - Margaret Hartley retires from InHANSE

 
Professor Mehanna talks to Quest

Professor Mehanna talks to Quest

14 Dec 18 - Prof Mehanna talks about the rise of HPV and head and neck cancer in the University of Birmingham Website Quest article

 
 

Prof Mehanna interview with eCancer Conferences

6 Dec 18 - Prof Mehanna talks to eCancer Conferences about De-ESCALaTE Study results

 
Charity appeal

Find out more about our £1m Charity appeal for the AcceleraTED cancer Treatment programme.